Bleuler seeks to redefine clinical management with advanced artificial intelligence and personalized solutions.

The project aims to improve patients' quality of life and optimize healthcare system costs.

52Platform, a leader in neuroscientific innovation, has announced Bleuler, a revolutionary project aimed at developing a platform to transform the treatment of schizophrenia. Designed with the most advanced capabilities of artificial intelligence, Bleuler aspires to provide personalized solutions based on accurate data. This international project collaborates with Synaptia Health Group in Spain, MJN Neuro, the National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez" in Mexico, Rey Juan Carlos University, and the investment fund Robby & Co.

Schizophrenia affects more than 25 million people worldwide. This disorder poses significant challenges due to variability in patient responses to current treatments. Bleuler, still in the study phase, focuses on developing an innovative clinical approach that combines electroencephalographic biomarkers and advanced cognitive assessments through artificial intelligence.

"Bleuler has the potential to revolutionize schizophrenia healthcare," said Adrián Trejo de la Rosa, CEO and co-founder of 52Platform. "This project is a step toward more precise treatment, which will improve patients' quality of life and give physicians reliable technological tools for making critical decisions. Our vision does not stop here; we want to expand this model to other neurological disorders and continue leading the future of personalized medicine."

The development of Bleuler will be possible thanks to a grant of €973,811.33 from a total budget of €1,604,067, awarded by the Centre for Technological Development and Innovation (CDTI, E.P.E.), a Public Business Entity under the Ministry of Science, Innovation and Universities. This funding, under its program supporting high-impact R&D projects, will allow for advancements in research, validation of the technology, and refinement of the platform design.

Technological innovation at the service of patients

Bleuler aims to detect clinical changes in patients early and adjust treatments according to their individual needs. Current studies include the development of wearable devices capable of monitoring brain activity from home, combined with automated cognitive analysis systems. These tools are designed to improve the quality of care and reduce unnecessary hospitalizations.

The project is expected to be ready for implementation by November 2026. This goal reinforces the commitment of collaborators to provide a solution that optimizes schizophrenia treatment in both public and private institutions. In addition to the clinical impact, Bleuler aims to improve the sustainability of the healthcare system in the long term by reducing costs associated with prolonged treatments. Although the platform is still under development, the projected advancements promise to significantly benefit patients and healthcare systems.

"Bleuler marks the beginning of a new era in personalized medicine," concluded Trejo de la Rosa. "We are committed to developing innovative solutions that not only transform the treatment of schizophrenia but also set new standards for other complex disorders."

About Robby & Co

Based in Palo Alto, California, Robby & Co is an innovative Venture Capital firm focused on supporting and empowering neurodivergent talent, with the team's own experiences serving as the starting point, as the majority of its members are neurodivergent.

Media Contact
Company Name: Robby & Co LLC
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://www.52platform.com